We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation of a Molecular Prognostic Test for Eye Melanoma

This study has been withdrawn prior to enrollment.
(It has come to our attention that the site was not necessary for our research project.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00406120
First Posted: December 4, 2006
Last Update Posted: May 17, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Washington University School of Medicine
  Purpose
Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.

Condition Intervention
Uveal Neoplasms Choroid Neoplasms Iris Neoplasms Procedure: Fine needle aspiration biopsy

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Estimated Enrollment: 2000
Study Start Date: January 2007
Estimated Study Completion Date: December 2017
Detailed Description:
We have discovered a gene expression profile derived from primary uveal melanomas that accurately predicts which patients will develop metastasis. Tumors with a class 1 gene expression signature have a very low risk, and those with a class 2 signature have a high risk of metastasis. The molecular test was initially performed on tissue obtained from enucleated eyes using commercial microarray platforms. We are now able to perform the molecular test on fine needle biopsy specimens, and we have developed a customized test that has greater dynamic range and sensitivity than commercial microarray platforms. The goal of this study is to validate the prognostic accuracy of the customized platform by performing the molecular test on primary uveal melanomas obtained from enucleation, local tumor resection or fine needle biopsy. Each sample will be diagnosed as either class 1, class 2 or indeterminate. Outcomes will be collected and the ability of the molecular diagnosis to predict metastasis will be evaluated at regular intervals.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnosis of melanoma of the iris, ciliary body and/or choroid
  • treatment to include enucleation, radiotherapy or local tumor resection

Exclusion Criteria:

  • evidence of marked tumor necrosis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406120


Locations
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: J. William Harbour, MD Washington University School of Medicine
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00406120     History of Changes
Other Study ID Numbers: 98-0042-A
First Submitted: November 29, 2006
First Posted: December 4, 2006
Last Update Posted: May 17, 2007
Last Verified: May 2007

Keywords provided by Washington University School of Medicine:
eye
uvea
iris
choroid
ciliary body
melanoma
iris melanoma
choroidal melanoma
ciliary body melanoma
uveal melanoma
posterior uveal melanoma
prognosis
metastasis
genetic testing
molecular testing
gene expression profiling

Additional relevant MeSH terms:
Neoplasms
Melanoma
Choroid Neoplasms
Uveal Neoplasms
Iris Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Choroid Diseases
Uveal Diseases
Iris Diseases